For the study, 2,285 patients were assigned to receive rosuvastatin, 10mg daily, while 2,289 patients were given a placebo.

At the end of the three-year study, the researchers found that 29 per cent of patients in the rosuvastatin group died from any cause compared with 28 per cent in the placebo group.

In addition, more patients from the rosuvastatin group - 57 per cent - were admitted to hospital.

In the placebo group, just 56 per cent of patients were admitted to hospital.

Comment below and tell us what you think